IMVT: Rega marang dodolan Immunovant Inc
Immunovant, Inc. (IMVT) maintains business stability by developing specialized treatments for rare pathologies in the US. This historical P/S chart serves as an indicator of market confidence, with recorded as the baseline value. Immunovant, Inc. (IMVT) is developing advanced antibodies for the therapy of immune disorders, aiming to promptly complete final molecule trials prior to the international launch of its products.
Immunovant Corp (IMVT) - rincian metrik lan laporan keuangan
- rega saham lan target rega konsensus:
- informasi kapitalisasi pasar:
- data nilai buku modal saham:
- statistik kawajiban utang lan likuiditas:
Rasio Total Utang marang Ekuitas Immunovant, Inc.|IMVT - Rasio utang jangka dawa marang ekuitas|Utang jangka cendhak marang modal Immunovant Therapeutics|IMVT - Utang perusahaan|Rasio utang marang nilai buku Immunovant Corp|IMVT - Utang jangka dawa perusahaan|Utang jangka cendhak Immunovant|Likuiditas cepet immunovant.com
- data bathi resik lan rasio valuasi:
IMVT - Bathi resik|Proyeksi bathi mangsa ngarep Immunovant, Inc.|IMVT - Rasio rega marang bathi|Rasio rega marang bathi mangsa ngarep Immunovant Inc|IMVT - Pangali rega marang bathi tumrap wutah|Koefisien nilai perusahaan marang bathi operasional sadurunge panyusutan Immunovant Corp|IMVT - Bathi operasional sadurunge ngurangi amortisasi|Bathi saben saham sajroning taun lumaku Immunovant|IMVT - Bathi resik saben saham (EPS TTM)|Owah-owahan bathi resik saben saham taun-ka-taun sajrone rolas wulan pungkasan immunovant.com|IMVT - Wutah bathi saben saham ing taun lumaku|Proyeksi kacepetan wutah bathi saben saham kanggo taun ngarep Immunovant, Inc.
- data total pendapatan lan volume dodolan:
Analisis fundamental perusahaan:immunovant.com (IMVT)
The P/S multiple measures the market value of a single ruble of revenue, allowing for an assessment of asset monetization efficiency and the risk of overpaying for a business during a period of stagnant sales. For Immunovant, Inc. (IMVT), whose value is based on the momentum of monoclonal antibody development without current commercial products, the company's rolling P/S reflects market expectations for future trial phases and the issuer's overall financial stability.
Pesaing Immunovant, Inc.
argenx.com - Rasio kapitalisasi marang pendapatan|Multiplikator P/S BNTX (BioNTech)|Abivax Pharma (ABVX) - Rega marang dodolan|ADMA Bio - Multiplikator P/S|Koefisien rega marang pendapatan Protagonist Corp PTGX|Kiniksa Pharmaceuticals (KNSA) - Rasio rega marang pendapatan|Kapitalisasi marang pendapatan grifols.com|Rasio rega marang pendapatan Adaptive Biotechnologies Corporation|Kapitalisasi marang pendapatan Celldex Therapeutics Inc (CLDX)|Kapitalisasi marang pendapatan AUPH (Aurinia Pharma)|Multiplikator P/S BioCryst Corp (BCRX)|Rasio rega marang pendapatan Vera Therapeutics, Inc. VERA|DNTH: Rasio kapitalisasi marang pendapatan|PHVS - Rasio rega marang pendapatan|Rega marang dodolan AbCellera Biologics Inc.|TRML (Tourmaline Corp) - Kapitalisasi marang pendapatan|PGEN (Precigen Corp) - Rasio rega marang pendapatan|PHAR (Pharming Group N.V.) - Multiplikator P/S|Multiplikator P/S nektar.com|Rasio rega marang pendapatan Upstream Bio (UPB)|Zenas Bio - Rasio kapitalisasi marang pendapatan|Immunome Corp - Kapitalisasi marang pendapatan|Kapitalisasi marang volume dodolan GOSS (Gossamer Bio Corp.)|KALV: Kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan SEPN (septerna.com)|PVLA: Multiplikator P/S|SVRA - Koefisien rega marang pendapatan|Rasio rega marang pendapatan Rigel Pharmaceuticals Inc|Rasio kapitalisasi marang pendapatan ANAB (AnaptysBio Inc.)|Multiplikator P/S ATXS|Kapitalisasi marang pendapatan engene.com ENGN|RAPT Therapeutics - Kapitalisasi marang pendapatan|Koefisien rega marang pendapatan Aerovate Therapeutics, Inc. (JBIO)|Aclaris - Multiplikator P/S|Koefisien rega marang pendapatan Kyverna Therapeutics, Inc KYTX|Tiziana Life Sciences (TLSA) - Rasio rega marang pendapatan|Kapitalisasi marang pendapatan cabalettabio.com|Kapitalisasi marang pendapatan VTYX|Rasio rega marang pendapatan THTX|Kapitalisasi marang pendapatan AVTX (Avalo Therapeutics Inc.)|Kapitalisasi marang volume dodolan ELDN|Rasio rega marang pendapatan Agenus AGEN|CLYM (climbbio.com) - Rasio rega marang dodolan|Zura Bio - Multiplikator P/S|Rasio kapitalisasi pasar marang pendapatan ATYR (aTyr Pharma Inc)|ADAG: Multiplikator P/S|Ikena Oncology (IMA) - Multiplikator P/S|Rasio rega marang pendapatan Shattuck Labs Inc|EQ: Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan Connect Biopharma (CNTB)|Kapitalisasi marang pendapatan immunic-therapeutics.com IMUX|Multiplikator P/S ATRA (Atara Bio)|Multiplikator P/S InflaRx NV IFRX|XFOR: Kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan ACET (Adicet Bio)|CELU: Multiplikator P/S|INMB - Koefisien rega marang pendapatan|Rasio rega marang pendapatan Barinthus Bio|Kapitalisasi marang pendapatan Kezar Life Sciences Inc (KZR)|Rasio rega marang pendapatan SAB Biotherapeutics (SABS)|Kapitalisasi marang pendapatan akaritx.com AKTX|Enlivex Therapeutics Ltd. - Kapitalisasi marang pendapatan|Multiplikator P/S Q32 Bio Inc QTTB|GOVX - Rasio rega marang pendapatan|EDSA (Edesa Biotech Corp) - Rasio kapitalisasi marang pendapatan|IBIO: Multiplikator P/S|Rega marang dodolan Carisma Therapeutics Inc. (CARM)|XTLB (XTL Biopharmaceuticals Ltd.) - Multiplikator P/S|Bolt Bio (BOLT) - Koefisien rega marang pendapatan|Rasio rega marang pendapatan HCW Biologics Inc. (HCWB)|Kapitalisasi marang pendapatan aptevotherapeutics.com APVO|Rasio rega marang pendapatan AIM ImmunoTech Inc. AIM|ADTX - Kapitalisasi marang pendapatan|GRI: Kapitalisasi marang pendapatan|XRTX - Multiplikator P/S|ReShape Lifesciences (HIND) - Rasio rega marang pendapatan|Rasio kapitalisasi marang pendapatan REVB|Rasio rega marang pendapatan Indaptus Therapeutics|Rega marang dodolan scinai.com SCNI|Kapitalisasi marang pendapatan CALI (CalciMedica, Inc.)|Rasio rega marang pendapatan AFMD (affimed.com)|Multiplikator P/S ALLK (Allakos)|Multiplikator P/S HOOKIPA Pharma, Inc. HOOK|IGMS - Rasio rega marang pendapatan|ITOS (iteostherapeutics.com) - Rasio kapitalisasi marang pendapatan|OCEA (Ocean Biomedical) - Kapitalisasi marang pendapatan|TCBP: Kapitalisasi marang volume dodolan|Kapitalisasi marang pendapatan THRD
